Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating BiomarkersOA
Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers
Haixia Cheng;Yuchen Jiao;Mei Liu;Lingying Wu;Guangwen Yuan;Leilei Liang;Tiantian Wang;Jiarun Zhu;Hongying Yang;Zhendiao Zhou;Pei Wang;Qianqian Song
Laboratory of Cell and Molecular Biology&State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaLaboratory of Cell and Molecular Biology&State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaLaboratory of Cell and Molecular Biology&State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Gynecologic Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Gynecologic Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Gynecologic Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Gynecologic Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaLaboratory of Cell and Molecular Biology&State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaPeking University Cancer Hospital Yunnan Hospital/Yunnan Provincial Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,ChinaLaboratory of Cell and Molecular Biology&State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaLaboratory of Cell and Molecular Biology&State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaLaboratory of Cell and Molecular Biology&State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China
circulating tumor DNAcopy number alterationsovarian cancerTP53 mutations
circulating tumor DNAcopy number alterationsovarian cancerTP53 mutations
《肿瘤学创新（英文）》 2025 (4)
25-35,11
This study was partly supported by the National Key R&D Program of China(Grant No.2016YFC13037040)and the Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences(Grant No.2022-RC310-08).
评论